Metabolomics in the study of kidney diseases

Nature Reviews Nephrology

Volumn 8, Issue 1, 2012, Pages 22-33

  Weiss, Robert H ^a   Kim, Kyoungmi ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; GENTAMICIN; HIPPURIC ACID; INDICAN; MELAMINE; MERCURIC CHLORIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT; TOBRAMYCIN;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; AMINOACIDURIA; CANCER DIAGNOSIS; CHRONIC KIDNEY DISEASE; CITRIC ACID CYCLE; CREATININE CLEARANCE; DEPRESSION; DIABETES INSIPIDUS; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; ESSENTIAL HYPERTENSION; FANCONI RENOTUBULAR SYNDROME; GAS CHROMATOGRAPHY; GENOMICS; GLOMERULUS FILTRATION RATE; GLUCOSURIA; GLYCOLYSIS; HUMAN; KETONURIA; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; METABOLOMICS; MICROALBUMINURIA; NEPHRECTOMY; NEPHROTOXICITY; NONHUMAN; PATTERN RECOGNITION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS; UREMIA; URINALYSIS;

BIOLOGICAL MARKERS; HUMANS; KIDNEY DISEASES; METABOLOMICS;

EID: 84455169596     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.152     Document Type: Review

References (71)

1. German, J. B., Hammock, B. D. & Watkins, S. M. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics 1, 3-9 (2005).
2. Kim, K. et al. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol. Cell. Proteomics 8, 558-570 (2009).
3. Calvani, R. et al. Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype. Int. J. Obes. (Lond.) 34, 1095-1098 (2010).
4. Romick-Rosendale, L. E. et al. NMR-based metabonomics analysis of mouse urine and fecal extracts following oral treatment with the broad-spectrum antibiotic enrofloxacin (Baytril). Magn. Reson. Chem. 47 (Suppl. 1), S36-S46 (2009).
5. Martin, F. P. et al. Dietary modulation of gut functional ecology studied by fecal metabonomics. J. Proteome Res. 9, 5284-5295 (2010).
6. 1H NMR) in rats. Toxicol. Appl. Pharmacol. 249, 114-126 (2010).
7. 1H-NMR-based metabonomics. Am. J. Physiol. Renal Physiol. 298, F461-F470 (2010).
8. Nicholson, J. K. & Lindon, J. C. Systems biology: metabonomics. Nature 455, 1054-1056 (2008).
9. Jellum, E., Stokke, O. & Eldjarn, L. Application of gas chromatography, mass spectrometry, and computer methods in clinical biochemistry. Anal. Chem. 46, 1099-1106 (1973).
10. Shoemaker, J. D. & Elliott, W. H. Automated screening of urine samples for carbohydrates, organic and amino acids after treatment with urease. J. Chromatogr. 562, 125-138 (1991).
11. Kuhara, T. et al. Pilot study of gas chromatographic-mass spectrometric screening of newborn urine for inborn errors of metabolism after treatment with urease. J. Chromatogr. B Biomed. Sci. Appl. 731, 141-147 (1999). (Pubitemid 29376424)
12. Kuhara, T. Gas chromatographic-mass spectrometric urinary metabolome analysis to study mutations of inborn errors of metabolism. Mass Spectrom. Rev. 24, 814-827 (2005). (Pubitemid 41641699)
13. Wishart, D. S. et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 35, D521-D526 (2007). (Pubitemid 46056263)
14. Pauling, L., Robinson, A. B., Teranishi, R. & Cary, P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc. Natl Acad. Sci. USA 68, 2374-2376 (1971).
15. Horning, E. C. & Horning, M. G. Metabolic profiles: gas-phase methods for analysis of metabolites. Clin. Chem. 17, 802-809 (1971).
16. Kind, T., Tolstikov, V., Fiehn, O. & Weiss, R. H. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal. Biochem. 363, 185-195 (2007). (Pubitemid 46428214)
17. Lindon, J. C. & Nicholson, J. K. Analytical techniques for metabonomics and metabolomics, and multi-omic information recover y. Trends Anal. Chem. 27, 194-204 (2008). (Pubitemid 351436617)
18. Kind, T. et al. FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal. Chem. 81, 10038-10048 (2009).
19. Dehaven, C. D., Evans, A. M., Dai, H. & Lawton, K. A. Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J. Cheminform. 2, 9 (2010).
20. Saude, E. J. & Sykes, B. D. Urine stability for metabolomic studies: effects of preparation and storage. Metabolomics 3, 19-27 (2007). (Pubitemid 46453528)
21. Gika, H. G., Theodoridis, G. A. & Wilson, I. D. Liquid chromatography and ultra-performance liquid chromatography-mass spectrometry fingerprinting of human urine: sample stability under different handling and storage conditions for metabonomics studies. J. Chromatogr. A 1189, 314-322 (2008).
22. Gu, H. et al. Monitoring diet effects via biofluids and their implications for metabolomics studies. Anal. Chem. 79, 89-97 (2007). (Pubitemid 46095034)
23. Slupsky, C. M. et al. Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. Anal. Chem. 79, 6995-7004 (2007). (Pubitemid 47438678)
24. Gika, H. G., Theodoridis, G. A., Wingate, J. E. & Wilson, I. D. Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J. Proteome Res. 6, 3291-3303 (2007). (Pubitemid 47310213)
25. Katajamaa, M. & Oresic, M. Data processing for mass spectrometry-based metabolomics. J. Chromatogr. A 1158, 318-328 (2007). (Pubitemid 47021150)
26. Sreekumar, A. et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914 (2009).
27. Kim, K. et al. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS 15, 293-303 (2011).
28. Wang, W. et al. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal. Chem. 75, 4818-4826 (2003). (Pubitemid 37139783)
29. Oresic, M. et al. Phenotype characterisation using integrated gene transcript, protein and metabolite profiling. Appl. Bioinformatics 3, 205-217 (2004). (Pubitemid 41043906)
30. van den Berg, R. A., Hoefsloot, H. C., Westerhuis, J. A., Smilde, A. K. & van der Werf, M. J. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 7, 142 (2006).
31. Westfall, P. H. & Young, S. S. Resampling-based multiple testing: examples and methods for P-value adjustment (John Wiley & Sons, New York, 1993).
32. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Statist. Soc. Series B Stat. Methodol. 57, 289-300 (1995).
33. Taylor, S. L. et al. A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am. J. Physiol. Renal Physiol. 298, F909-F922 (2010).
34. Rubingh, C. M. et al. Assessing the performance of statistical validation tools for megavariate metabolomics data. Metabolomics 2, 53-61 (2006). (Pubitemid 44184264)
35. Mahadevan, S., Shah, S. L., Marrie, T. J. & Slupsky, C. M. Analysis of metabolomic data using support vector machines. Anal. Chem. 80, 7562-7570 (2008).
36. 1H nuclear magnetic resonance. J. Biomed. Biotechnol. 2011, 158094 (2011).
37. Ein-Dor, L., Zuk, O. & Domany, E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc. Natl Acad. Sci. USA 103, 5923-5928 (2006).
38. Niemann, C. U. & Serkova, N. J. Biochemical mechanisms of nephrotoxicity: application for metabolomics. Expert Opin. Drug Metab. Toxicol. 3, 527-544 (2007). (Pubitemid 351324962)
39. Wishart, D. S. Metabolomics: the principles and potential applications to transplantation. Am. J. Transplant. 5, 2814-2820 (2005). (Pubitemid 43923941)
40. Niwa, T. Update of uremic toxin research by mass spectrometry. Mass Spectrom. Rev. 30, 510-521 (2011).
41. Kikuchi, K. et al. Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878, 1662-1668 (2010).
42. Niwa, T., Maeda, K., Ohki, T., Saito, A. & Kobayashi, K. A gas chromatographic-mass spectrometric analysis for phenols in uremic serum. Clin. Chim. Acta 110, 51-57 (1981). (Pubitemid 11191441)
43. Toyohara, T. et al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens. Res. 33, 944-952 (2010).
44. Boudonck, K. J. et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol. Pathol. 37, 280-292 (2009).
45. Star, R. A. Treatment of acute renal failure. Kidney Int. 54, 1817-1831 (1998). (Pubitemid 28533609)
46. Xu, E. Y. et al. Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicants. Chem. Res. Toxicol. 21, 1548-1561 (2008).
47. Perroud, B. et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol. Cancer 5, 64 (2006).
48. Melnick, J. Z., Baum, M. & Thompson, J. R. Aminoglycoside-induced Fanconi's syndrome. Am. J. Kidney Dis. 23, 118-122 (1994). (Pubitemid 24021756)
49. Pratt, C. B. et al. Ifosfamide, Fanconi's syndrome, and rickets. J. Clin. Oncol. 9, 1495-1499 (1991).
50. Portilla, D. et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int. 69, 2194-2204 (2006). (Pubitemid 43882106)
51. Perroud, B., Ishimaru, T., Borowsky, A. D. & Weiss, R. H. Grade-dependent proteomics characterization of kidney cancer. Mol. Cell. Proteomics 8, 971-985 (2009).
52. Park, J. C. et al. A metabonomic study on the biochemical effects of doxorubicin in rats using (1)H-NMR spectroscopy. J. Toxicol. Environ. Health A 72, 374-384 (2009).
53. Xie, G. et al. Metabonomic evaluation of melamine-induced acute renal toxicity in rats. J. Proteome Res. 9, 125-133 (2010).
54. 1H NMR spectroscopy. Toxicol. Appl. Pharmacol. 234, 314-325 (2009).
55. Broumand, B. Diabetes: changing the fate of diabetics in the dialysis unit. Blood Purif. 25, 39-47 (2007). (Pubitemid 46005750)
56. Lu, D. et al. 13C NMR isotopomer analysis reveals a connection between pyruvate cycling and glucose-stimulated insulin secretion (GSIS). Proc. Natl Acad. Sci. USA 99, 2708-2713 (2002). (Pubitemid 34240525)
57. Jensen, M. V. et al. Metabolic cycling in control of glucose-stimulated insulin secretion. Am. J. Physiol. Endocrinol. Metab. 295, E1287-E1297 (2008).
58. Cline, G. W., Lepine, R. L., Papas, K. K., Kibbey, R. G. & Shulman, G. I. 13C NMR isotopomer analysis of anaplerotic pathways in INS-1 cells. J. Biol. Chem. 279, 44370-44375 (2004). (Pubitemid 39430841)
59. Savage, D. B., Petersen, K. F. & Shulman, G. I. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 87, 507-520 (2007). (Pubitemid 47084679)
60. Holland, W. L. & Summers, S. A. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 29, 381-402 (2008). (Pubitemid 351831506)
61. Lucio, M. et al. Insulin sensitivity is reflected by characteristic metabolic fingerprints-a Fourier transform mass spectrometric non-targeted metabolomics approach. PLoS ONE 5, e13317 (2010).
62. Suhre, K. et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 5, e13953 (2010).
63. Zhao, X. et al. Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics 6, 362-374 (2010).
64. Connor, S. C., Hansen, M. K., Corner, A., Smith, R. F. & Ryan, T. E. Integration of metabolomics and transcriptomics data to aid biomarker discovery in type 2 diabetes. Mol. Biosyst. 6, 909-921 (2010).
65. Ganti, S. et al. Urinary acylcarnitines are altered in kidney cancer. Int. J. Cancer http://dx.doi.org/10.1002/ijc.26274.
66. Marchesini, G. et al. Elimination of infused branched-chain amino-acids from plasma of patients with non-obese type 2 diabetes mellitus. Clin. Nutr. 10, 105-113 (1991).
67. Alam, A. & Perrone, R. D. Management of ESRD in patients with autosomal dominant polycystic kidney disease. Adv. Chronic Kidney Dis. 17, 164-172 (2010).
68. Saude, E. J., Adamko, D., Rowe, B. H., Marrie, T. & Sykes, B. D. Variation of metabolites in normal human urine. Metabolomics 3, 439-451 (2007). (Pubitemid 350090674)
69. van der Greef, J., Hankemeier, T. & McBurney, R. N. Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics 7, 1087-1094 (2006). (Pubitemid 44644787)
70. Bayet-Robert, M., Morvan, D., Chollet, P. & Barthomeuf, C. Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses. Breast Cancer Res. Treat. 120, 613-626 (2010).
71. Ji, Y. et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics- informed pharmacogenomics. Clin. Pharmacol. Ther. 89, 97-104 (2011).